Abbott Laboratories $ABT Stock: Crossmark Global Holdings Inc. Grows Position

Key Points

• Crossmark Global Holdings increased its Abbott stake by 14.4% in the third quarter to 368,095 shares valued at approximately $36.4 million. Institutional investors collectively own 75.18% of ABT.
• Abbott reported quarterly EPS of $1.42 and revenue of $13.01 billion, with sales up 14.5% year over year. The company reaffirmed its full-year EPS guidance, though it lowered its 2026 sales-growth outlook because of weakness in medical devices.
• Abbott plans to separate its roughly $8.5 billion Nutrition business into an independent publicly traded company by the end of 2027. Shares recently traded at $100.59, while analysts maintain a “Moderate Buy” consensus with an average price target of $118.88; the company also declared a quarterly dividend of $0.63 per share.

Crossmark Global Holdings Inc. increased its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 14.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 368,095 shares of the healthcare product maker's stock after acquiring an additional 46,248 shares during the period. Crossmark Global Holdings Inc.'s holdings in Abbott Laboratories were worth $36,379,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABT. Bank of America Corp DE purchased a new position in shares of Abbott Laboratories in the second quarter worth $1,603,607,000. Legal & General Group Plc bought a new stake in Abbott Laboratories in the second quarter valued at $1,082,524,000. Flossbach Von Storch SE bought a new stake in Abbott Laboratories in the second quarter valued at $902,938,000. Jupiter Topco LLC purchased a new position in Abbott Laboratories during the 2nd quarter valued at $732,788,000. Finally, BlackRock Inc. increased its position in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 1.8%

NYSE:ABT opened at $100.59 on Thursday. The company's 50 day moving average price is $105.47 and its 200-day moving average price is $98.28. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The stock has a market cap of $174.06 billion, a price-to-earnings ratio of 32.55, a PEG ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The firm had revenue of $13.01 billion during the quarter, compared to analysts' expectations of $12.99 billion. During the same quarter in the previous year, the business earned $1.30 earnings per share. The company's revenue was up 14.5% on a year-over-year basis. On average, equities research analysts forecast that Abbott Laboratories will post 5.53 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Third-quarter adjusted earnings per share were $1.42, in line with the company’s consensus estimate, while revenue rose 14.5% year over year to $13.01 billion, slightly exceeding expectations. Comparable sales increased 7%, and Abbott reaffirmed its full-year adjusted EPS guidance. Abbott third-quarter results
• Positive Sentiment: Management announced plans to separate its approximately $8.5 billion Nutrition business—including Ensure, Similac, Glucerna, Pedialyte and PediaSure—into an independent, publicly traded company through a tax-free distribution to shareholders, targeted for completion by the end of 2027. Abbott believes the transaction could accelerate growth and expand margins in its remaining businesses. Abbott Nutrition separation announcement
• Positive Sentiment: New product approvals and European authorization for Abbott’s Cologuard Plus colorectal cancer test expand its diagnostics portfolio and could support longer-term growth. Cologuard Plus European approval
• Neutral Sentiment: The spin-off is intended to unlock value by allowing Abbott and the new Nutrition company to pursue separate strategies, but investors must assess execution, tax and transition risks before the separation is completed.
• Negative Sentiment: Abbott lowered its 2026 sales-growth forecast, citing weakness in medical devices. The reduced outlook suggests near-term operating momentum may be softer than previously expected, despite continued strength in areas such as continuous glucose monitoring. Reuters report on Abbott’s outlook
• Negative Sentiment: Some analysts characterized the $1.42 adjusted EPS result as a slight miss against a $1.43 estimate. Combined with the lower sales outlook and uncertainty surrounding the Nutrition separation, that has outweighed the quarter’s revenue growth and caused the stock to decrease.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ABT shares. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. JPMorgan Chase & Co. lifted their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. BTIG Research boosted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research report on Friday, July 17th. Citigroup increased their price target on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Finally, Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $118.88.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.